MCID: SWN001
MIFTS: 42

Swine Influenza

Categories: Respiratory diseases, Infectious diseases

Aliases & Classifications for Swine Influenza

MalaCards integrated aliases for Swine Influenza:

Name: Swine Influenza 12 76 55 3 15 73
Influenza Due to Influenza a Virus Subtype H1n1 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050211

Summaries for Swine Influenza

CDC : 3 Swine influenza is a respiratory disease of pigs caused by type A influenza viruses that regularly cause outbreaks of influenza in pigs. Influenza viruses that commonly circulate in swine are called “swine influenza viruses” or “swine flu viruses.” Like human influenza viruses, there are different subtypes and strains of swine influenza viruses. The main swine influenza viruses circulating in U.S. pigs in recent years have been, swine triple reassortant (tr) H1N1 influenza virus, trH3N2 virus, and trH1N2 virus.

MalaCards based summary : Swine Influenza, also known as influenza due to influenza a virus subtype h1n1, is related to avian influenza and influenza, and has symptoms including fever, lethargy and lack of appetite. An important gene associated with Swine Influenza is GP2 (Glycoprotein 2). The drugs Vitamin C and Vitamin A have been mentioned in the context of this disorder. Affiliated tissues include respiratory tract of pigs, testes and lung.

Disease Ontology : 12 An influenza that results in infection located in respiratory tract of pigs and humans, has material basis in Influenza C virus, or has material basis in Influenza A virus subtypes (H1N1, H1N2, H3N1, H3N2, and H2N3), which are transmitted by direct contact with infected pigs. The infection in humans has symptom fever, has symptom lethargy, has symptom lack of appetite, has symptom coughing, has symptom runny nose, has symptom sore throat, has symptom nausea, has symptom vomiting, and has symptom diarrhea.

Wikipedia : 76 Swine influenza is an infection caused by any one of several types of swine influenza viruses. Swine... more...

Related Diseases for Swine Influenza

Diseases related to Swine Influenza via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 31)
# Related Disease Score Top Affiliating Genes
1 avian influenza 29.9 HAS1 TNF
2 influenza 11.1
3 pneumonia 10.4
4 aging 10.1
5 foodborne botulism 10.0 GP2 HAS1
6 pleuropneumonia 9.9
7 systemic lupus erythematosus 9.9
8 legionnaire disease 9.9
9 legionnaires' disease 9.9
10 respiratory failure 9.9
11 cerebritis 9.9
12 lymphopenia 9.9
13 appendicitis 9.9
14 lupus erythematosus 9.9
15 narcolepsy 9.9
16 rheumatoid arthritis 9.7
17 myocardial infarction 9.7
18 arthritis 9.7
19 thrombocytopenia 9.7
20 vaccinia 9.7
21 plague 9.7
22 mouth disease 9.7
23 acute disseminated encephalomyelitis 9.7
24 myocarditis 9.7
25 chronic fatigue syndrome 9.7
26 neuropathy 9.7
27 smallpox 9.7
28 parainfluenza virus type 3 9.7
29 virus associated hemophagocytic syndrome 9.7
30 hemophagocytic syndrome associated with an infection 9.7
31 dysostosis 9.7 NEU1 POLR1A

Graphical network of the top 20 diseases related to Swine Influenza:



Diseases related to Swine Influenza

Symptoms & Phenotypes for Swine Influenza

Symptoms:

12
  • fever
  • lethargy
  • lack of appetite
  • coughing
  • runny nose
  • sore throat
  • nausea
  • vomiting
  • diarrhea

UMLS symptoms related to Swine Influenza:


coughing, fever, pruritus, snoring

Drugs & Therapeutics for Swine Influenza

Drugs for Swine Influenza (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
2
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
3
Lactitol Investigational Phase 4,Phase 2,Not Applicable 585-86-4 3871
4 Retinol palmitate Phase 4
5 Micronutrients Phase 4
6 Trace Elements Phase 4
7 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Vitamins Phase 4
9 Antibodies Phase 4,Phase 2,Phase 1,Not Applicable
10 Immunoglobulins Phase 4,Phase 2,Phase 1,Not Applicable
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Antioxidants Phase 4
13 Protective Agents Phase 4
14 Antipyretics Phase 4
15 Antiviral Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 MF59 oil emulsion Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Hemagglutinins Phase 4,Phase 2,Phase 1
18 Immunosuppressive Agents Phase 4
19 retinol Nutraceutical Phase 4
20
Zanamivir Approved, Investigational Phase 3,Phase 2 139110-80-8 60855
21
Oseltamivir Approved Phase 3,Phase 2,Not Applicable 204255-11-8, 196618-13-0 65028
22
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
23
Butyric Acid Experimental, Investigational Phase 3 107-92-6 264
24 Adjuvants, Immunologic Phase 2, Phase 3,Phase 3,Not Applicable
25 Anti-Inflammatory Agents Phase 3,Phase 2
26 Cortisol succinate Phase 3
27 Hydrocortisone 17-butyrate 21-propionate Phase 3
28 Hydrocortisone acetate Phase 3
29 Hydrocortisone-17-butyrate Phase 3
30
Thymalfasin Approved, Investigational Phase 2 62304-98-7
31 Agglutinins Phase 1, Phase 2
32 Anti-Bacterial Agents Phase 2
33 Antibiotics, Antitubercular Phase 2
34 Pharmaceutical Solutions Phase 2
35 Rho(D) Immune Globulin Phase 2
36 gamma-Globulins Phase 2
37 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2,Not Applicable
38 Hypolipidemic Agents Phase 2,Not Applicable
39 Immunoglobulins, Intravenous Phase 2
40 Antibodies, Monoclonal Phase 2
41 Anticholesteremic Agents Phase 2,Not Applicable
42 Lipid Regulating Agents Phase 2,Not Applicable
43 Antimetabolites Phase 2,Not Applicable
44 Rosuvastatin Calcium Phase 2,Not Applicable 147098-20-2
45 Calcium, Dietary Phase 2,Not Applicable
46
Aluminum sulfate Approved Phase 1 10043-01-3
47 Interleukin-2
48 Gastrointestinal Agents Not Applicable
49 Aluminum phosphate Not Applicable
50 Antacids Not Applicable

Interventional clinical trials:

(show top 50) (show all 156)
# Name Status NCT ID Phase Drugs
1 The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A Unknown status NCT01127282 Phase 4 Vitamin (vitamin A 15 mg,C 500 mg, E 400IU);Placebo (digestive tablet)
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
4 Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects Completed NCT01069367 Phase 4
5 H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients Completed NCT01111162 Phase 4
6 A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines Completed NCT01004653 Phase 4
7 Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults Completed NCT01008137 Phase 4
8 Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV Completed NCT01002040 Phase 4
9 Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients Completed NCT01022905 Phase 4
10 Safety of H1N1 Influenza Vaccination in Pregnant Women Completed NCT01842997 Phase 4
11 Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children Completed NCT01000831 Phase 4
12 Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults Completed NCT01001026 Phase 4
13 Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine Completed NCT01000584 Phase 4
14 Clinical Study to Evaluate Antibody and Cell Mediated Immunity of A/H1N1 Influenza Vaccine in Healthy Subjects Completed NCT01079273 Phase 4
15 Vaccination Against Influenza in Autoimmune Diseases Completed NCT01065285 Phase 4
16 Phase IV Clinical Trial of an Influenza Split Vaccine Anflu Completed NCT00556062 Phase 4
17 Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine Completed NCT01023776 Phase 4
18 A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults Completed NCT00945893 Phase 4
19 A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age Completed NCT00946101 Phase 4
20 Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older Completed NCT01114620 Phase 4
21 A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season Completed NCT01457027 Phase 4
22 Direct and Indirect Protection by Influenza Vaccine Given to Children in India Completed NCT00934245 Phase 4
23 Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children Withdrawn NCT01097941 Phase 4
24 Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine Unknown status NCT01582633 Phase 2, Phase 3
25 Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month Unknown status NCT01040078 Phase 3
26 Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects Completed NCT01000207 Phase 2, Phase 3
27 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years) Completed NCT00972816 Phase 2, Phase 3
28 Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India Completed NCT01053143 Phase 3
29 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years) Completed NCT00973700 Phase 3
30 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults Completed NCT00973349 Phase 2, Phase 3
31 Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects Completed NCT00996138 Phase 2, Phase 3
32 Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection Completed NCT01032408 Phase 3
33 Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors Completed NCT01031719 Phase 3
34 Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults Completed NCT00989287 Phase 3
35 Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes Completed NCT00992511 Phase 3
36 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age Completed NCT00971906 Phase 3
37 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age Completed NCT00971542 Phase 3
38 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age Completed NCT00971100 Phase 3
39 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age Completed NCT00970177 Phase 3
40 Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza? Completed NCT01001325 Phase 3
41 Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus Completed NCT01032395 Phase 3
42 Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months Completed NCT00996307 Phase 2, Phase 3
43 Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age Completed NCT01051661 Phase 3
44 A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine Completed NCT01201902 Phase 3
45 A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection Terminated NCT00979667 Phase 3 Oseltamivir;Zanamivir;Placebo of Oseltamivir
46 Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu Terminated NCT01014364 Phase 3 hydrocortisone;isotonic saline
47 Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults Unknown status NCT01155037 Phase 2
48 The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine Unknown status NCT01336166 Phase 2
49 Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients Unknown status NCT01055990 Phase 2
50 A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months Completed NCT00956046 Phase 2

Search NIH Clinical Center for Swine Influenza

Genetic Tests for Swine Influenza

Anatomical Context for Swine Influenza

The Foundational Model of Anatomy Ontology organs/tissues related to Swine Influenza:

19
Respiratory Tract Of Pigs

MalaCards organs/tissues related to Swine Influenza:

41
Testes, Lung, Heart, T Cells, Neutrophil, Brain

Publications for Swine Influenza

Articles related to Swine Influenza:

(show top 50) (show all 619)
# Title Authors Year
1
Effects of the S42 residue of the H1N1 swine influenza virus NS1 protein on interferon responses and virus replication. ( 29587786 )
2018
2
Emergence of Eurasian Avian-Like Swine Influenza A (H1N1) Virus from an Adult Case in Fujian Province, China. ( 29797225 )
2018
3
Isolation and molecular characterization of an H5N1 swine influenza virus in China in 2015. ( 29164401 )
2018
4
Effects of Isatis root polysaccharide in mice infected with H3N2 swine influenza virus. ( 29890386 )
2018
5
Swine influenza viruses in Northern Vietnam in 2013-2014. ( 29967457 )
2018
6
Regional patterns of genetic diversity in swine influenza A viruses in the United States from 2010 to 2016. ( 29624873 )
2018
7
Molecular subtyping of European swine influenza viruses and scaling to high-throughput analysis. ( 29316958 )
2018
8
Monoclonal Antibody Against HA Protein of the European Avian-Like H1N1 Swine Influenza Virus. ( 29630477 )
2018
9
Evidence of infection with avian, human, and swine influenza viruses in pigs in Cairo, Egypt. ( 29075888 )
2018
10
Substitution of D701N in the PB2 protein could enhance the viral replication and pathogenicity of Eurasian avian-like H1N1 swine influenza viruses. ( 29717109 )
2018
11
Maternally-derived antibodies do not inhibit swine influenza virus replication in piglets but decrease excreted virus infectivity and impair post-infectious immune responses. ( 29519509 )
2018
12
Molecular evolution of H1N1 swine influenza in Guangdong, China, 2016-2017. ( 29477550 )
2018
13
Intradermal immunization with inactivated swine influenza virus and adjuvant polydi(sodium carboxylatoethylphenoxy)phosphazene (PCEP) induced humoral and cell-mediated immunity and reduced lung viral titres in pigs. ( 29454517 )
2018
14
Subtyping of Swine Influenza Viruses Using a High-Throughput Real-Time PCR Platform. ( 29872645 )
2018
15
A Naturally Occurring Deletion in the Effector Domain of H5N1 Swine Influenza Virus Nonstructural Protein 1 Regulates Viral Fitness and Host Innate Immunity. ( 29563291 )
2018
16
Corrigendum to &amp;quot;Molecular epidemiology of swine influenza A viruses in the Southeastern United States, highlights regional differences in circulating strains'' [Vet. Microbiol. 211 (2017) 174-179]. ( 29274732 )
2018
17
Genome Sequence of an Unusual Reassortant H1N1 Swine Influenza Virus Isolated from a Pig in Russia, 2016. ( 28883131 )
2017
18
Coinfection modulates inflammatory responses, clinical outcome and pathogen load of H1N1 swine influenza virus and Haemophilus parasuis infections in pigs. ( 29202835 )
2017
19
Letter to the editor: Just a coincidence? Two severe human cases due to swine influenza (SIV) A(H1N1)v in Europe, October 2016. ( 28300531 )
2017
20
Kaempferol ameliorates H9N2 swine influenza virus-induced acute lung injury by inactivation of TLR4/MyD88-mediated NF-I_B and MAPK signaling pathways. ( 28262619 )
2017
21
Pathogenicity and transmission of a swine influenza A(H6N6) virus. ( 28400591 )
2017
22
Genetic analysis of human and swine influenza A viruses isolated in Northern Italy during 2010-2015. ( 28791803 )
2017
23
Hidden authority study data have come to light: besides narcolepsy, the swine influenza vaccine Pandemrix caused type 1 diabetes. ( 27995691 )
2017
24
Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs. ( 28057521 )
2017
25
Estimation of the transmission parameters for swine influenza and porcine reproductive and respiratory syndrome viruses in pigs from weaning to slaughter under natural conditions. ( 28237230 )
2017
26
The PB2-K627E mutation attenuates H3N2 swine influenza virus in cultured cells and in mice. ( 29175013 )
2017
27
Influence of microclimate conditions on the cumulative exposure of nursery pigs to swine influenza A viruses. ( 28940764 )
2017
28
Feral Swine in the United States Have Been Exposed to both Avian and Swine Influenza A Viruses. ( 28733290 )
2017
29
Pig Lung Immune Cytokine Response to the Swine Influenza Virus and the <i>Actinobacillus Pleuropneumoniae</i> Infection. ( 29978082 )
2017
30
Harnessing Local Immunity for an Effective Universal Swine Influenza Vaccine. ( 28475122 )
2017
31
Protective efficacy of a virus-vectored multi-component vaccine against porcine reproductive and respiratory syndrome virus, porcine circovirus type 2 and swine influenza virus. ( 29091579 )
2017
32
Molecular epidemiology of swine influenza A viruses in the Southeastern United States, highlights regional differences in circulating strains. ( 29102115 )
2017
33
Pathogenicity and transmission of triple reassortant H3N2 swine influenza A viruses is attenuated following Turkey embryo propagation. ( 28284612 )
2017
34
Epigallocatechin-3-gallate inhibits TLR4 signaling through the 67-kDa laminin receptor and effectively alleviates acute lung injury induced by H9N2 swine influenza virus. ( 28858723 )
2017
35
Comparison of mono- and co-infection by swine influenza A viruses and porcine respiratory coronavirus in porcine precision-cut lung slices. ( 28779714 )
2017
36
PA-X protein decreases replication and pathogenicity of swine influenza virus in cultured cells and mouse models. ( 28622865 )
2017
37
Authors' reply: Two severe human cases due to swine influenza A (H1N1)v in October 2016 in Europe were chronologic coincident yet distinct events. ( 28300530 )
2017
38
Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice. ( 28941982 )
2017
39
Protection of human influenza vaccines against a reassortant swine influenza virus of pandemic H1N1 origin using a pig model. ( 28267619 )
2017
40
Kinetics of single and dual infection of pigs with swine influenza virus and Actinobacillus pleuropneumoniae. ( 28284596 )
2017
41
Characterization of Monoclonal Antibodies against HA Protein of H1N1 Swine Influenza Virus and Protective Efficacy against H1 Viruses in Mice. ( 28786930 )
2017
42
A Single-Amino-Acid Substitution at Position 225 in HA Alters the Transmissibility of Eurasian Avian-like H1N1 Swine Influenza Virus in Guinea Pigs. ( 28814518 )
2017
43
Fatal swine influenza A H1N1 and Mycoplasma pneumoniae coinfection in a child. ( 28393730 )
2016
44
In Vivo Validation of Predicted and Conserved T Cell Epitopes in a Swine Influenza Model. ( 27411061 )
2016
45
Truncation of C-terminal 20 amino acids in PA-X contributes to adaptation of swine influenza virus in pigs. ( 26912401 )
2016
46
Determination of current reference viruses for serological study of swine influenza viruses after the introduction of pandemic 2009 H1N1 (pdmH1N1) in Thailand. ( 27355862 )
2016
47
An Underestimated Co-infection: Swine Influenza and Pneumonia Due to Legionella pneumophila. ( 27650238 )
2016
48
The Molecular Determinants of Antibody Recognition and Antigenic Drift in the H3 Hemagglutinin of Swine Influenza A Virus. ( 27384658 )
2016
49
Severe acute respiratory infection caused by swine influenza virus in a child necessitating extracorporeal membrane oxygenation (ECMO), the Netherlands, October 2016. ( 27934581 )
2016
50
Mycoplasma hyopneumoniae does not affect the interferon-related anti-viral response but predisposes the pig to a higher inflammation following swine influenza virus infection. ( 27498789 )
2016

Variations for Swine Influenza

Expression for Swine Influenza

Search GEO for disease gene expression data for Swine Influenza.

Pathways for Swine Influenza

GO Terms for Swine Influenza

Biological processes related to Swine Influenza according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of insulin secretion GO:0050796 8.96 SLC8B1 TNF
2 animal organ morphogenesis GO:0009887 8.8 FGD1 TNF TREH

Molecular functions related to Swine Influenza according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity, acting on glycosyl bonds GO:0016798 8.62 NEU1 TREH

Sources for Swine Influenza

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....